Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
43
PBYI Quote, Financials, Valuation and Earnings
Last price:
$5.28
Seasonality move
:
16.8%
Day range:
$5.16 - $5.32
52-week range:
$2.58 - $6.12
Dividend yield:
0%
P/E ratio:
7.01x
P/S ratio:
1.23x
P/B ratio:
2.27x
Volume:
453.2K
Avg. volume:
574.5K
1-year change:
67.41%
Market cap:
$261.5M
Revenue:
$230.5M
EPS (TTM):
$0.74
Analysts' Opinion
-
Consensus RatingPuma Biotechnology, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $3.50, Puma Biotechnology, Inc. has an estimated downside of -32.56% from its current price of $5.29.
-
Price Target UpsideAccording to analysts, the highest upside price target is $5.00 representing -100% upside increase from its current price of $5.29.
Fair Value
-
According to the consensus of 1 analyst, Puma Biotechnology, Inc. has -32.56% downside to fair value with a price target of $3.50 per share.
PBYI vs. S&P 500
-
Over the past 5 trading days, Puma Biotechnology, Inc. has overperformed the S&P 500 by 4.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Puma Biotechnology, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Puma Biotechnology, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Puma Biotechnology, Inc. reported revenues of $54.5M.
Earnings Growth
-
Puma Biotechnology, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Puma Biotechnology, Inc. reported earnings per share of $0.17.
Enterprise value:
206.1M
EV / Invested capital:
1.32x
Price / LTM sales:
1.23x
EV / EBIT:
6.14x
EV / Revenue:
0.97x
PEG ratio (5yr expected):
0.13x
EV / Free cash flow:
4.81x
Price / Operating cash flow:
6.07x
Enterprise value / EBITDA:
4.61x
Gross Profit (TTM):
$163M
Return On Assets:
17.96%
Net Income Margin (TTM):
17.44%
Return On Equity:
38.49%
Return On Invested Capital:
23.32%
Operating Margin:
17.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $229.1M | $243.6M | $212M | $80.5M | $54.5M | |
| Gross Profit | $173.9M | $168.8M | $163M | $51.4M | $42.3M | |
| Operating Income | $28.5M | $32.4M | $33.6M | $22.1M | $9.6M | |
| EBITDA | $39.3M | $44M | $44.7M | $25M | $12.3M | |
| Diluted EPS | $0.07 | $0.47 | $0.74 | $0.41 | $0.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $136.9M | $122.4M | $125.4M | $156.8M | $143.6M | |
| Total Assets | $226.3M | $198.8M | $203.6M | $220.7M | $202.9M | |
| Current Liabilities | $116.3M | $60M | $67.4M | $110.4M | $82.7M | |
| Total Liabilities | $237.2M | $176.6M | $164.9M | $149.6M | $87.6M | |
| Total Equity | -$10.9M | $22.2M | $38.7M | $71.1M | $115.3M | |
| Total Debt | $117.2M | $110.9M | $107.6M | $81M | $38.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $24.2M | $33.8M | $43M | $11M | $9.7M | |
| Cash From Investing | -$22.8M | -$26.3M | -$11.5M | $259K | $506K | |
| Cash From Financing | $2.4M | -$22.5M | -$45.2M | -$11.2M | -$11.3M | |
| Free Cash Flow | $11.6M | $33.7M | $42.9M | $11M | $9.7M | |
PBYI
Sector
Market Cap
$261.5M
$28.4M
Price % of 52-Week High
84.8%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
4.25%
-1.32%
1-Year Price Total Return
58.72%
-22.19%
Beta (5-Year)
1.177
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.04
200-day SMA
Buy
Level
$3.98
Bollinger Bands (100)
Buy
Level
4.01 - 5.43
Chaikin Money Flow
Sell
Level
-29.2M
20-day SMA
Buy
Level
$5.03
Relative Strength Index (RSI14)
Buy
Level
55.91
ADX Line
Buy
Level
20.11
Williams %R
Sell
Level
-10.4167
50-day SMA
Buy
Level
$5.12
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Sell
Level
-3.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.0022)
Buy
CA Score
(Annual)
Level (-0.2262)
Buy
Beneish M-Score
(Annual)
Level (-2.8856)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (0.4195)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Stock Forecast FAQ
In the current month, PBYI has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PBYI average analyst price target in the past 3 months is $3.50.
-
Where Will Puma Biotechnology, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Puma Biotechnology, Inc. share price will drop to $3.50 per share over the next 12 months.
-
What Do Analysts Say About Puma Biotechnology, Inc.?
Analysts are divided on their view about Puma Biotechnology, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Puma Biotechnology, Inc. is a Sell and believe this share price will rise from its current level to $2.00.
-
What Is Puma Biotechnology, Inc.'s Price Target?
The price target for Puma Biotechnology, Inc. over the next 1-year time period is forecast to be $3.50 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PBYI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Puma Biotechnology, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of PBYI?
You can purchase shares of Puma Biotechnology, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Puma Biotechnology, Inc. shares.
-
What Is The Puma Biotechnology, Inc. Share Price Today?
Puma Biotechnology, Inc. was last trading at $5.28 per share. This represents the most recent stock quote for Puma Biotechnology, Inc.. Yesterday, Puma Biotechnology, Inc. closed at $5.29 per share.
-
How To Buy Puma Biotechnology, Inc. Stock Online?
In order to purchase Puma Biotechnology, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PBYI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PBYI
Sector
P/E ratio
7.01x
23.66x
PEG ratio
0.13x
-0.01x
P/B ratio
2.27x
1.84x
Price / LTM sales
1.23x
1.60x
Growth Metrics
PBYI
Sector
Revenue growth
-32.37%
4.85%
Earnings growth
-57.99%
11.15%
Revenue (5-year growth)
-3.28%
6.45%
Earnings forecast
$0.09
-$0.20
Profitability
PBYI
Sector
Profitability FY 2024
$166.1M
$3.6M
Return on invested capital
23.32%
-30.98%
Return on assets
17.96%
-27.62%
Return on equity
38.49%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
PBYI
Sector
Total cash
$96.5M
$27.2M
Short term investments
$31.7M
$25.7M
Total assets
$214.7M
$79.9M
Long term debt
$38.6M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
